IRONWOOD PHARMACEUTICALS, INC. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of -$771.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2024-12-31 was -$991.00K, a 309.07% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2024-09-30 was $561.00K, a 20.91% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2024-06-30 was -$451.00K.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2024-03-31 was -$172.00K.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was -$771.00K.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was -$1.05M, a 212.26% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was $938.00K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month as first filed | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$771.00K 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | -$991.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$430.00K derived: sum of 2 quarters · filed 2026-02-26 | -$881.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.05M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $561.00K 10-Q · filed 2025-11-10 | $110.00K derived: sum of 2 quarters · filed 2025-11-10 | -$62.00K 10-Q · filed 2025-11-10 | $412.00K derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$451.00K 10-Q · filed 2025-08-11 | -$623.00K 10-Q · filed 2025-08-11 | -$149.00K derived: sum of 3 quarters · filed 2025-08-11 | $315.00K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$172.00K 10-Q · filed 2025-05-12 | $302.00K derived: sum of 2 quarters · filed 2025-05-12 | $766.00K derived: sum of 3 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $938.00K 10-K · filed 2025-03-31 | $900.00K 10-K · filed 2024-02-16 | $938.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $464.00K 10-Q · filed 2024-11-07 | $464.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |